Cargando…

Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer

Metformin is the most widely administered anti-diabetic agent worldwide. In patients receiving metformin for metabolic syndrome or diabetes, it reduces the incidence and improves the survival of breast cancer (BC) patients. We have previously shown that metformin is particularly potent against tripl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wahdan-Alaswad, RS, Edgerton, SM, Salem, HS, Thor, AD
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959056/ https://www.ncbi.nlm.nih.gov/pubmed/29780974 http://dx.doi.org/10.4172/2476-2261.1000129

Ejemplares similares

Glucose promotes breast cancer aggression and reduces metformin efficacy
por: Wahdan-Alaswad, Reema, et al.
Publicado: (2013)

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
por: Wahdan-Alaswad, Reema, et al.
Publicado: (2020)

Thyroid Hormone and Estrogen Promote Endocrine Resistance, Proliferation, Dedifferentiation, and Cancer Stem Cells in Steroid Receptor-Positive Breast Cancers
por: Wahdan-Alaswad, Reema S, et al.
Publicado: (2021)

High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells
por: Varghese, Sharon, et al.
Publicado: (2019)

Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation
por: Shi, Peiguo, et al.
Publicado: (2017)

Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
por: Anselmino, L. E., et al.
Publicado: (2021)

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
por: Lee, Jung Ok, et al.
Publicado: (2019)

Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway
por: Yang, Lihui, et al.
Publicado: (2021)

Association of androgen receptor expression with glucose metabolic features in triple-negative breast cancer
por: Lee, Reeree, et al.
Publicado: (2022)

Metformin and oxyphotodynamic therapy as a novel treatment approach for triple-negative breast cancer
por: Pei, Xiaofeng, et al.
Publicado: (2020)

Metabolic characterization of triple negative breast cancer
por: Cao, Maria D, et al.
Publicado: (2014)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Metabolic reprogramming in triple-negative breast cancer
por: Wang, Zhanyu, et al.
Publicado: (2020)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Targeting Metabolic Remodeling in Triple Negative Breast Cancer in a Murine Model
por: García-Castillo, Verónica, et al.
Publicado: (2017)

MIG‐6 is essential for promoting glucose metabolic reprogramming and tumor growth in triple‐negative breast cancer
por: He, Jiabei, et al.
Publicado: (2021)

Glutamine addiction promotes glucose oxidation in triple-negative breast cancer
por: Quek, Lake-Ee, et al.
Publicado: (2022)

Triple-negative breast cancer and the potential for targeted therapy
por: Jhan, Jing-Ru, et al.
Publicado: (2017)

Targeting MYC for triple-negative breast cancer treatment
por: Klauber-DeMore, Nancy, et al.
Publicado: (2018)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses
por: Green-Tripp, Gabriela, et al.
Publicado: (2022)

“Sister” miRNAs in cancers
por: Wahdan-Alaswad, Reema, et al.
Publicado: (2013)

Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside?
por: Marini, Cecilia, et al.
Publicado: (2021)

Link between glucose metabolism and epithelial-to-mesenchymal transition drives triple-negative breast cancer migratory heterogeneity
por: Schwager, Samantha C., et al.
Publicado: (2022)

Triple Negative Breast Cancer and Breast Epithelial Cells Differentially Reprogram Glucose and Lipid Metabolism upon Treatment with Triterpenic Acids
por: Guerra, Ângela R., et al.
Publicado: (2020)

Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
por: Park, So-Yeon, et al.
Publicado: (2019)

Metabolic Response of Triple-Negative Breast Cancer to Folate Restriction
por: Coleman, Michael F., et al.
Publicado: (2021)

Dual Effect of Combined Metformin and 2-Deoxy-D-Glucose Treatment on Mitochondrial Biogenesis and PD-L1 Expression in Triple-Negative Breast Cancer Cells
por: Repas, Jernej, et al.
Publicado: (2022)

Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
por: Davison, Craig, et al.
Publicado: (2021)

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
por: de Heer, E. C., et al.
Publicado: (2023)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer
por: Sambi, Manpreet, et al.
Publicado: (2020)

Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities
por: Lanning, Nathan J., et al.
Publicado: (2017)

Triple-negative breast cancer: new perspectives for targeted therapies
por: Tomao, Federica, et al.
Publicado: (2015)

CAPER as a therapeutic target for triple negative breast cancer
por: Campbell, Mallory C., et al.
Publicado: (2018)

Targeting triple-negative breast cancers with the Smac-mimetic birinapant
por: Lalaoui, Najoua, et al.
Publicado: (2020)

Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer
por: Nakhjavani, Maryam, et al.
Publicado: (2019)

Targeting DNA methylation for treating triple-negative breast cancer
por: Yu, Jia, et al.
Publicado: (2019)

Novel strategies to target chemoresistant triple-negative breast cancer
por: Venkatesh, Jaganathan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_41u5aj0d3gmrngp77saqgni9id